BioIVT held its annual HEPATOPAC® User Group Meeting in Boston on October 2018. Below are the presentations from our panel of industry experts illustrating how HEPATOPAC Technology can enhance drug discovery programs and is used to investigate the ADME-Tox profile of drugs in development.
Download the slides from the presentations below:
miR-122 Release in Exosomes Precedes Overt Tolvaptan-Induced Necrosis in the Human HEPATOPAC® Model
Speaker: Merrie Mosedale, Ph.D., Research Assistant Professor, University of North Carolina, Chapel Hill
Evaluation of Transporter-Enzyme Interplay in Drug Disposition Using Micropatterned Co-cultured Hepatocytes (HEPATOPAC® Technology)
Speaker: Paresh P. Chothe, Ph.D., Research Scientist, Vertex Pharmaceuticals Inc.
How to Identify Cytochromes P450 that Mediate the Metabolism of Low Turnover Compounds Utilizing Human Pooled HEPATOPAC® Cultures
Speaker: Sheri Smith, Senior Scientist, Merck & Co, Inc
Simultaneous Assessments of ADME Readouts Using the HEPATOPAC® model for a Novel Hepatitis B Virus Inhibitor
Speaker: Nicole A. Kratochwil, Ph.D., Research Pharmacologist, Roche Pharmaceutical
Integrated In Vitro Tools to Assess Transporter-Mediated Taurocholate Disposition
Speaker: Steven W. Louie, Director Transporter Sciences, BioIVT
Development of a Novel Human 3D In Vitro Model for Evaluating New Anti-Fibrotic Drugs
Speaker: Kenneth R. Brouwer, Ph.D., RPh., VP of ADME-Tox, BioIVT